Understanding how defects in DNA replication affect treatment response in triple-negative breast cancer
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer
This study is looking at how certain issues with DNA in triple-negative breast cancer might affect how well immunotherapy works, so we can find out which patients are most likely to benefit from this treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11007209 on NIH RePORTER |
What this research studies
This research investigates the relationship between defects in the DNA replication stress response and the effectiveness of immune checkpoint therapy in patients with triple-negative breast cancer (TNBC). By identifying a specific gene signature associated with these defects, the study aims to determine which patients are most likely to benefit from immunotherapy. The approach includes analyzing tumor samples to assess the presence of this gene signature and its correlation with treatment outcomes. The ultimate goal is to enhance therapeutic strategies for TNBC patients by tailoring treatments based on their tumor characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who are considering or currently undergoing immune checkpoint therapy.
Not a fit: Patients with non-triple-negative breast cancer or those who do not have the identified gene signature may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with triple-negative breast cancer, improving their chances of a positive treatment outcome.
How similar studies have performed: Previous research has shown promising results in using genetic signatures to predict treatment responses in various cancers, suggesting that this approach may also be effective for triple-negative breast cancer.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Lin, Shiaw-Yih — University of Tx Md Anderson Can Ctr
- Study coordinator: Lin, Shiaw-Yih
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.